HLS Therapeutics Inc.
HLTRF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$133.95M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $133.95 Million |
|---|---|
| Enterprise Value | $162.40 Million |
| Earnings per Share | $-0.4 |
| Beta | 0.85 |
| Outstanding Shares | 34,000,000 |
Return
| Return on Equity | -15.49% |
|---|---|
| Return on Assets | -6.66% |
| Return on Invested Capital | -3.71% |
Valuation & Multiples
| P/E Ratio | -10.35 |
|---|---|
| PEG | 16.48 |
| Price to Sales | 3.2 |
| Price to Book Ratio | 3.2 |
| Enterprise Value to Revenue | 2.88 |
| Enterprise Value to EBIT | -43.98 |
| Enterprise Value to Net Income | -19 |
| Total Debt to Enterprise | 0.26 |
| Debt to Equity | 0.76 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.08
Consensus analyst estimateRevenue Estimate
$14.15 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.07
Consensus analyst estimateRevenue Estimate
$14.87 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About HLS Therapeutics Inc.
85 employees
CEO: Craig Stuart Millian
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. I...